Education
About Us
Working with TipRanks
Follow Us
Invion (IVIXF)
OTHER OTC:IVIXF
IVIXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.04 - $0.78
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
$6.83M
Enterprise Value$7.22M
Total Cash (Recent Filing)$736.45K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-2.88
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding85,647,255
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)89.00
Price to Sales (P/S)347.81
P/FCF Ratio-389.20
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue4.93
Enterprise Value/Gross Profit-35.66
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.78 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $6.83M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Mar 04, 2026 which is in 166 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Aug 27, 2025. The company reported -$0.061 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.061.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 85,647,255 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -$0.061 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
Invion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IVIXF Sentiment 100%
Sector Average 73%
Sector Average 73%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.14%
12-Months-Change
Fundamentals
Return on Equity
-74.92%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Invion
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Ecofibre
―
Epsilon Healthcare Limited
―
Bod Australia Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---